Patents by Inventor Natalia De Val

Natalia De Val has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
    Publication number: 20240083954
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 14, 2024
    Inventors: Leopold Kong, Ian A. Wilson, Natalia de Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
    Patent number: 11767347
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 26, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20220098244
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
    Patent number: 11236134
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 1, 2022
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20200165303
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 28, 2020
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
    Patent number: 10647748
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 12, 2020
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20190048043
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 14, 2019
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Soluble HIV-1 envelope glycoprotein trimers
    Patent number: 10058604
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 28, 2018
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Richard Wyatt, Andrew Ward, Karen Tran, Shailendra Kumar, Jidnyasa Ingale, Javier Guenaga, Yu Feng, Viktoriya Dubrovskaya, Natalia de Val Alda
  • SOLUBLE HIV-1 ENVELOPE GLYCOPROTEIN TRIMERS
    Publication number: 20170035877
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 9, 2017
    Inventors: Richard Wyatt, Andrew Ward, Karen Tran, Shailendra Kumar, Jidnyasa Ingale, Javier Guenaga, Yu Feng, Viktoria Dubrowskaya, Natalia de Val Alta